Dechra Pharmaceuticals PLC

DCHPFOTCHealthcare

$46.90

$-0.10(-0.21%)

Market Cap$5.3B

P/E Ratio—

52W High$47.4

52W Low$30.0

Avg Volume13

Open$46.90

Beta0.51

PE Ratio Market Cap Forecast

Dechra Pharmaceuticals PLC (DCHPF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

dchpf · pe ratio · data through Jun 30, 2023

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Dechra Pharmaceuticals PLC (DCHPF) measures how much investors pay for each dollar of the company's trailing earnings. DCHPF's current PE ratio of N/A is calculated by dividing its stock price of $46.90 by its TTM earnings per share of -$0.25.

N/A

P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2023-06-30

Forward P/E

N/A

—

EPS (TTM)

-$0.25

TTM · diluted EPS

PEG Ratio

-1.57

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dechra Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2004 – 2023 · Annual

PE Ratio (TTM)

5Y Avg 73.0x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 19 fiscal years · Front-end computed

Average

63.0x

19-yr mean

Median

61.2x

19-yr midpoint

Minimum

13.7x

Lowest year

Maximum

96.1x

Highest year

13.7x
MinQ1 · 25%61.2x
MedianQ3 · 75%96.1x
Max

Historically Low

At N/A, DCHPF's current P/E is lower than in 0% of its annual fiscal year readings over the past 19 years — historically low.

0th percentileHigher than 0 of 19 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Medical - Pharmaceuticals · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
Dechra Pharmaceuticals PLCYou DCHPF	$5.3B	N/A	—	-$0.25
Abcam plc ABCZF	$5.1B	N/A	—	$0.00
Mediclinic International plc ANHGY	$4.0B	N/A	—	—
Ascentage Pharma Group International ASPHF	$1.7B	N/A	—	-$3.40
McKesson Europe AG CAKFY	$5.4B	N/A	—	-$0.05
Galenica AG GALNF	$5.7B	25.35x	-3.0%	$3.63
Hangzhou Tigermed Consulting Co., Ltd. HNGZY	$6.2B	26.89x	+3.0%	$1.04
Industry Average 2 peers with valid PE	—	26.12x	baseline	—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2023-06-30Latest FY2023	—	$-0.25	—
2022-06-30 FY2022	59.62x	$0.54	-30.4%
2021-06-30 FY2021	85.70x	$0.51	+2.0%
2020-06-30 FY2020	83.99x	$0.33	-6.7%
2019-06-30 FY2019	89.99x	$0.30	+98.0%
2018-06-30 FY2018	45.45x	$0.37	-18.5%
2017-06-30 FY2017	55.77x	$0.28	-33.5%
2016-06-30 FY2016	83.90x	$0.14	+84.7%
2015-06-30 FY2015	45.41x	$0.22	+232.5%
2014-06-30 FY2014	13.66x	$0.68	-72.9%

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $46.90 ÷ -$0.25 = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

DCHPF pe ratio · 6 questions

DCHPF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $46.90 and TTM EPS of -$0.25. Data sourced from Financial Modeling Prep via DCHPF's SEC 10-K and 10-Q filings.

DCHPF PE ratioWhat is DCHPF PE ratioCurrent PE ratio of DCHPFDCHPF PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dechra Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09